Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
14.99
+0.04 (0.27%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Avalo Therapeutics Revenue
In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.
Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
13,625.65
Revenue / Employee
$1,788
Employees
33
Market Cap
803.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.00K | -382.00K | -86.62% |
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
| Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.27% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Geron | 204.56M |
| Ginkgo Bioworks Holdings | 132.42M |
| Lexicon Pharmaceuticals | 41.47M |
| Inventiva | 2.81M |
| Attovia Therapeutics | 1.80M |
AVTX News
- 5 days ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Avalo Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 11 days ago - Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress - GlobeNewsWire
- 18 days ago - Avalo Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 24 days ago - Avalo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 1 month ago - Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim - TheFly
- 1 month ago - Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright - TheFly